Please ensure Javascript is enabled for purposes of website accessibility

Should Investors Be Concerned About DermTech?

By Keith Speights and Brian Orelli, PhD – Sep 12, 2021 at 8:57AM

Key Points

  • It's probably going to take a while for DermTech to gain widespread acceptance among doctors for its genomics-based melanoma test.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Be concerned? No. Be patient? Yes.

DermTech (DMTK 0.84%) stock skyrocketed earlier this year. Now, though, its shares are more than 50% below the previous highs. In this Motley Fool Live video recorded on Sept. 1, Motley Fool contributors Keith Speights and Brian Orelli address a viewer's question about whether there's reason to be concerned about DermTech.

10 stocks we like better than DermTech, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and DermTech, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of August 9, 2021


Keith Speights: Very quickly, Brian, let's hit one question before we end our segment. The question that's getting the most upvotes is from Dorian. Any cause for concern with DermTech, the ticker there is DMTK. Just really quickly. Do you know any reason for concern with this stock?

Brian Orelli: No. I think you've got to be in it for the long term. Let's quickly go back. DermTech has a melanoma test that they're changing the way doctors normally do tests for melanoma.

Normally doctors take a biopsy and now what they're doing is they're trying to put something before a biopsy, it's basically a piece of tape and it rips off some cells off the lesion that the doctor thinks might be melanoma. Then they send it to a lab and they do genetic testing on those cells and they can determine fairly accurately whether that melanoma is likely cancerous. Then you would avoid having to do a biopsy on all of the suspect lesions and you would only do a biopsy on ones that tested positive by the DermTech's test.

So basically you got to change doctors' habits. I think that can be very difficult. I think DermTech is finding that that's quite difficult. They need to get more and more doctors to use it. They need to get more and more coverage by insurance companies. As they do that, it'll grow in popularity by the doctors. So then they'll be able to ramp up -- there'll be hockey stick of ramping up sales and so,  I think that you have to wait for that hockey stick to actually happen.

Keith Speights owns shares of DermTech, Inc. The Motley Fool owns shares of and recommends DermTech, Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DermTech, Inc. Stock Quote
DermTech, Inc.
$2.41 (0.84%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.